Tumor-associated-antigens or osteosarcoma cell line lysates: Two efficient methods for in vitro generation of CTLs with special regard to MHC-I restriction

Fagioli, 2002, Trattamento dell’osteosarcoma delle estremità ad alto grado di malignità, Minerva, Ortop Traumatol, 53, 195 Bacci, 1993, Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremities: results in 164 patients pre-operatively treated with high doses of methotrexate followed by Cisplatin and Doxorubicin, Cancer, 72, 3227, 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C Saeter, 1991, Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study, J Clin Oncol, 9, 1766, 10.1200/JCO.1991.9.10.1766 Saeter, 1999, Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience, Acta Orthop Scand Suppl, 285, 74, 10.1080/17453674.1999.11744828 Meyers, 1998, Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol, J Clin Oncol, 16, 2452, 10.1200/JCO.1998.16.7.2452 Provisor, 1997, Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group, J Clin Oncol, 15, 76, 10.1200/JCO.1997.15.1.76 Saeter, 1995, Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival, Cancer, 15, 1084, 10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F Bacci, 2000, Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide, Oncol Rep, 7, 339 Fagioli, 2003, Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report, Haematologica, 88, ECR16 Kounami, 2005, Non-myeloablative allogenic peripheral blood stem cell transplantation in a patient with refractory osteosarcoma, Pediatr Transplant, 9, 342, 10.1111/j.1399-3046.2005.00290.x Fagioli, 2003, Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease, Acta Haematol, 110, 139, 10.1159/000072463 Bollard, 2003, Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease, Acta Haematol, 110, 139, 10.1159/000072463 Pardoll, 2002, T-cells take aim at cancer, PNAS, 99, 15840, 10.1073/pnas.262669499 Almand, 2000, Clinical significance of defective dendritic cell differentiation in cancer, Clin Cancer Res, 6, 1755 Gabrilovich, 2004, Mechanisms and functional significance of tumour-induced dendritic-cell defects, Nat Rev Immunol, 4, 941, 10.1038/nri1498 De Plaen, 1994, Structure, chromosomal localization, and expression of 12 genes of the MAGE family, Immunogenetics, 40, 360, 10.1007/BF01246677 Sudo, 1997, Expression of MAGE genes in osteosarcoma, J Orthop Res, 15, 128, 10.1002/jor.1100150119 Tureci, 1998, Expression of SSX genes in human tumors, Int J Cancer, 77, 19, 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2 Naka, 2002, Expression of SSX genes in human osteosarcomas, Int J Cancer, 98, 640, 10.1002/ijc.10277 Yang, 1999, Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients, Cancer Res, 59, 4056 Tsuda, 2001, Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides, J Orthop Res, 19, 346, 10.1016/S0736-0266(00)90031-7 Walter, 1995, Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor, N Engl J Med, 333, 1038, 10.1056/NEJM199510193331603 Straathof, 2003, Immunotherapy for Epstein-Barr virus-associated cancers in children, Oncologist, 8, 83, 10.1634/theoncologist.8-1-83 Dazzi, 1999, Donor lymphocyte infusions, Curr Opin Hematol, 6, 394, 10.1097/00062752-199911000-00007 Dudley, 2003, Adoptive-cell-transfer therapy for the treatment of patients with cancer, Nat Rev Cancer, 3, 666, 10.1038/nrc1167 Bakker, 1995, Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro, Cancer Res, 55, 5330 Fields, 1998, Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo, Proc Natl Acad Sci USA, 95, 9482, 10.1073/pnas.95.16.9482 Abdel-Wahab, 1998, Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280–288), induce pairs of T-cell cultures with similar phenotype and lytic activity, Cell Immunol, 186, 63, 10.1006/cimm.1998.1298 Hao, 2002, Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients, J Cancer Res Clin Oncol, 128, 507, 10.1007/s00432-002-0358-x Graff-Dubois, 2002, Generation of CTL recognizing an HLA-A∗0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy, J Immunol, 169, 575, 10.4049/jimmunol.169.1.575 Sato, 2003, A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells, Int Immunol, 15, 837, 10.1093/intimm/dxg081